enGene Holdings Management
Management criteria checks 0/4
enGene Holdings' CEO is Ron Cooper, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.02% of the company’s shares, worth $79.81K. The average tenure of the management team and the board of directors is 0.8 years and 1.4 years respectively.
Key information
Ron Cooper
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | less than a year |
| Board average tenure | 1.4yrs |
Recent management updates
CEO
Ron Cooper (61 yo)
less than a year
Tenure
Mr. Ronald H. W. Cooper, also known as Ron, is Chief Executive Officer & Director of enGene Holdings Inc. from July 20, 2024. Mr. Cooper is Independent Director and Chairman of C4 Therapeutics, Inc. from J...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Strategy & Operations Officer | 1.2yrs | US$1.03m | 0% $ 0 | |
| Chief Executive Officer & Director | less than a year | no data | 0.020% $ 79.8k | |
| Co-Founder & Chief Scientific Officer | 26yrs | US$341.75k | 0.20% $ 820.9k | |
| Co-Founder and Member of Scientific Advisory Board | no data | no data | no data | |
| CFO & Head of Business Development | 1.2yrs | no data | no data | |
| Chief Technology Officer | less than a year | no data | no data | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
| Senior VP of Human Resources | less than a year | no data | no data | |
| VP of Project Management & Head of Program Management | 5yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Senior VP of Regulatory Affairs | less than a year | no data | no data | |
| Senior VP of Clinical Development Operations | less than a year | no data | no data |
0.8yrs
Average Tenure
50yo
Average Age
Experienced Management: ENGN's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer & Director | less than a year | no data | 0.020% $ 79.8k | |
| Co-Founder and Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.1yrs | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Chairman | 1.8yrs | US$48.73k | 0.048% $ 196.9k | |
| Independent Director | 1.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 18.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Observer | no data | no data | no data |
1.4yrs
Average Tenure
62.5yo
Average Age
Experienced Board: ENGN's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 02:57 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
enGene Holdings Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Cheng | CGS International |
| Michael Schmidt | Guggenheim Securities, LLC |
| Andres Maldonado | H.C. Wainwright & Co. |